Physician profile
Michael C Turner
NPI 1629035647
$10,663.12
in general payments reported to CMS, 2019-2025
36 companies · $3,046 in 2025
The $3,046 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $226 · 2021: $612 · 2022: $1,675 · 2023: $1,426 · 2024: $2,403 · 2025: $3,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,851 · Travel and Lodging: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,851.05 |
| Travel and Lodging | $1,024.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,493.36 | 2019-2025 | Ffrct |
| Cleerly, INC. | $1,274.49 | 2023-2025 | Cleerly Labs, Cleerly Ischemia |
| Pfizer INC. | $1,142.95 | 2019-2025 | |
| United Imaging Healthcare North America, INC. | $1,024.41 | 2025 | N/A |
| Novartis Pharmaceuticals Corporation | $731.48 | 2019-2025 | Leqvio |
| E.R. Squibb & Sons, L.L.C. | $683.46 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $450.23 | 2022-2025 | Cds - Mct/Cem Monitoring, Watchman Flx, Watchman |
| Abbott Laboratories | $443.01 | 2019-2025 | Amplatzer Amulet, Thoratec Heartmate 3 Lvas Implant Kit, Xience Skypoint |
| Janssen Pharmaceuticals, INC | $358.90 | 2019-2023 | Xarelto |
| Amgen INC. | $327.41 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $300.82 | 2021-2024 | Nexletol, Nexlizet |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $276.89 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.54 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $251.02 | 2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $250.51 | 2022-2024 | Onpattro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $216.05 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $156.63 | 2019-2022 | |
| Novo Nordisk INC | $140.62 | 2023-2025 | Wegovy, Ozempic |
| Medtronic, INC. | $109.21 | 2025 | Symplicity G3 |
| Biosense Webster, INC. | $84.04 | 2022-2023 | Carto 3 |
| Astrazeneca Pharmaceuticals LP | $82.89 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $75.29 | 2019-2022 | |
| Gilead Sciences, INC. | $72.68 | 2019 | |
| Lundbeck LLC | $67.79 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $51.47 | 2024 | Arcalyst |
| Silk Road Medical, INC. | $49.64 | 2021-2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Regeneron Healthcare Solutions, INC. | $48.89 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $38.38 | 2023 | Inpefa |
| Kestra Medical Technology Services, INC. | $34.89 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $31.93 | 2025 | Uptravi |
| United Therapeutics Corporation | $30.98 | 2019 | |
| Recor Medical INC | $24.45 | 2024 | Paradise Renal Denervation System |
| Akcea Therapeutics, INC. | $23.20 | 2020 | |
| Abiomed | $19.30 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.55 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $16.76 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.